Apex Biotechnology Corp. (1733.TW)
TWD 29.0
(2.29%)
TWD 29.0
(2.29%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 531.11 Million TWD | -7.93% |
| 2022 | 576.83 Million TWD | 0.93% |
| 2021 | 571.51 Million TWD | 26.38% |
| 2020 | 452.22 Million TWD | -23.43% |
| 2019 | 590.57 Million TWD | 5.44% |
| 2018 | 560.1 Million TWD | 29.8% |
| 2017 | 431.51 Million TWD | -9.51% |
| 2016 | 476.84 Million TWD | -12.85% |
| 2015 | 547.13 Million TWD | 4.28% |
| 2014 | 524.67 Million TWD | -7.7% |
| 2013 | 568.44 Million TWD | -29.68% |
| 2012 | 808.36 Million TWD | 7.9% |
| 2011 | 749.2 Million TWD | -0.62% |
| 2010 | 753.87 Million TWD | 23.09% |
| 2009 | 612.44 Million TWD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 110.53 Million TWD | 7.16% |
| 2024 Q1 | 103.14 Million TWD | -24.49% |
| 2023 Q4 | 136.59 Million TWD | -0.5% |
| 2023 Q2 | 123.01 Million TWD | -8.35% |
| 2023 FY | 531.11 Million TWD | -7.93% |
| 2023 Q1 | 134.21 Million TWD | -14.98% |
| 2023 Q3 | 137.29 Million TWD | 11.61% |
| 2022 Q3 | 153.03 Million TWD | 14.53% |
| 2022 FY | 576.83 Million TWD | 0.93% |
| 2022 Q1 | 132.3 Million TWD | -9.08% |
| 2022 Q4 | 157.86 Million TWD | 3.16% |
| 2022 Q2 | 133.62 Million TWD | 1.0% |
| 2021 FY | 571.51 Million TWD | 26.38% |
| 2021 Q3 | 148.63 Million TWD | 17.12% |
| 2021 Q1 | 150.46 Million TWD | 40.85% |
| 2021 Q4 | 145.51 Million TWD | -2.1% |
| 2021 Q2 | 126.9 Million TWD | -15.66% |
| 2020 Q2 | 122.76 Million TWD | 17.95% |
| 2020 Q1 | 104.08 Million TWD | -55.34% |
| 2020 Q4 | 106.82 Million TWD | -9.89% |
| 2020 FY | 452.22 Million TWD | -23.43% |
| 2020 Q3 | 118.55 Million TWD | -3.43% |
| 2019 Q3 | 101.88 Million TWD | -23.78% |
| 2019 FY | 590.57 Million TWD | 5.44% |
| 2019 Q1 | 121.95 Million TWD | -5.71% |
| 2019 Q2 | 133.67 Million TWD | 9.61% |
| 2019 Q4 | 233.05 Million TWD | 128.74% |
| 2018 Q2 | 116.57 Million TWD | -6.5% |
| 2018 FY | 560.1 Million TWD | 29.8% |
| 2018 Q3 | 189.49 Million TWD | 62.54% |
| 2018 Q1 | 124.68 Million TWD | -23.86% |
| 2018 Q4 | 129.35 Million TWD | -31.74% |
| 2017 Q4 | 163.76 Million TWD | 59.07% |
| 2017 Q1 | 75.54 Million TWD | -15.36% |
| 2017 Q3 | 102.95 Million TWD | 15.35% |
| 2017 FY | 431.51 Million TWD | -9.51% |
| 2017 Q2 | 89.25 Million TWD | 18.14% |
| 2016 Q4 | 89.25 Million TWD | -1.94% |
| 2016 FY | 476.84 Million TWD | -12.85% |
| 2016 Q1 | 152.15 Million TWD | -11.37% |
| 2016 Q2 | 144.41 Million TWD | -5.09% |
| 2016 Q3 | 91.02 Million TWD | -36.97% |
| 2015 Q3 | 141.32 Million TWD | 24.75% |
| 2015 FY | 547.13 Million TWD | 4.28% |
| 2015 Q1 | 120.84 Million TWD | -17.13% |
| 2015 Q2 | 113.29 Million TWD | -6.25% |
| 2015 Q4 | 171.67 Million TWD | 21.47% |
| 2014 Q1 | 113.99 Million TWD | 7.01% |
| 2014 Q4 | 145.82 Million TWD | 15.65% |
| 2014 Q3 | 126.08 Million TWD | -9.14% |
| 2014 Q2 | 138.76 Million TWD | 21.73% |
| 2014 FY | 524.67 Million TWD | -7.7% |
| 2013 Q3 | 120.92 Million TWD | -28.52% |
| 2013 Q4 | 106.52 Million TWD | -11.91% |
| 2013 FY | 568.44 Million TWD | -29.68% |
| 2013 Q1 | 171.81 Million TWD | -9.73% |
| 2013 Q2 | 169.17 Million TWD | -1.53% |
| 2012 Q2 | 198.47 Million TWD | -15.52% |
| 2012 FY | 808.36 Million TWD | 7.9% |
| 2012 Q3 | 186.99 Million TWD | -5.78% |
| 2012 Q1 | 234.92 Million TWD | 3.62% |
| 2012 Q4 | 190.32 Million TWD | 1.78% |
| 2011 Q4 | 226.71 Million TWD | 4.29% |
| 2011 Q1 | 141.67 Million TWD | -24.48% |
| 2011 Q3 | 217.38 Million TWD | 33.0% |
| 2011 FY | 749.2 Million TWD | -0.62% |
| 2011 Q2 | 163.44 Million TWD | 15.37% |
| 2010 Q2 | 190.76 Million TWD | 11.64% |
| 2010 Q4 | 187.59 Million TWD | -8.33% |
| 2010 Q1 | 170.87 Million TWD | 0.0% |
| 2010 FY | 753.87 Million TWD | 23.09% |
| 2010 Q3 | 204.64 Million TWD | 7.28% |
| 2009 FY | 612.44 Million TWD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Sinphar Pharmaceutical Co.,Ltd. | 1.09 Billion TWD | 51.329% |
| Panion & Bf Biotech Inc. | 912.56 Million TWD | 41.8% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 757.3 Million TWD | 29.868% |
| GenMont Biotech Incorporation | 177.33 Million TWD | -199.497% |
| Abnova (Taiwan) Corporation | 173.91 Million TWD | -205.388% |
| Adimmune Corporation | 410.93 Million TWD | -29.246% |
| Tanvex BioPharma, Inc. | 59.7 Million TWD | -789.627% |
| Polaris Group | -137.9 Million TWD | 485.143% |
| Energenesis Biomedical CO.,LTD. | 5.22 Million TWD | -10061.01% |
| UnicoCell Biomed Co., Ltd. | 17.89 Million TWD | -2867.626% |
| PELL Bio-Med Technology Co. Ltd. | -26.14 Million TWD | 2131.813% |